DiaMedica Therapeutics (DMAC) Equity Ratio (2017 - 2026)

DiaMedica Therapeutics has reported Equity Ratio for 10 years, with the latest figure at 0.89 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 1.77% year-over-year to 0.89; the trailing twelve-month figure through Mar 2026 stood at 0.89 (up 1.77% YoY), and the FY2025 full-year result was 0.91, up 4.06% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.89, down from 0.91 in the prior quarter.
• The five-year high for Equity Ratio was 0.97 in Q1 2022, with the low at 0.86 in Q2 2025.
• Historically, Equity Ratio has averaged 0.92 across 5 years, with a median of 0.93 in 2022.
• Annual changes were most pronounced in 2024 — Equity Ratio advanced 5.22% — and 2025, when it retreated 8.21%.
• DiaMedica Therapeutics' Equity Ratio stood at 0.93 in 2022, then increased by 1.88% to 0.94 in 2023, then decreased by 6.8% to 0.88 in 2024, then gained by 4.06% to 0.91 in 2025, then fell by 2.67% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.91 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.